Program Announcement

for the

Defense Health Program
Department of Defense
Congressionally Directed Medical Research Programs

Autism Research Program

Clinical Trial Award

Funding Opportunity Number: W81XWH-14-ARP-CTA
Catalog of Federal Domestic Assistance Number: 12.420

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Deadline: 5:00 p.m. Eastern time (ET), June 10, 2014
- Invitation to Submit an Application: July 2014
- Application Submission Deadline: 11:59 p.m. ET, October 7, 2014
- End of Application Verification Period: 5:00 p.m. ET, October 13, 2014
- Peer Review: December 2014
- Programmatic Review: February 2015

Change for Fiscal Year 2014: The CDMRP eReceipt System has been replaced with the electronic Biomedical Research Application Portal (eBRAP). Principal Investigators and organizational representatives should register in eBRAP as soon as possible. All pre-applications must be submitted through eBRAP. In addition, applications submitted through Grants.gov will now be available for viewing, modification, and verification in eBRAP prior to the end of the application verification period.

This Program Announcement/Funding Opportunity is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Funding Opportunity Description</td>
<td>3</td>
</tr>
<tr>
<td>A. Program Description</td>
<td>3</td>
</tr>
<tr>
<td>B. FY14 ARP Areas of Interest</td>
<td>3</td>
</tr>
<tr>
<td>C. Award Information</td>
<td>3</td>
</tr>
<tr>
<td>D. Eligibility Information</td>
<td>5</td>
</tr>
<tr>
<td>E. Funding</td>
<td>5</td>
</tr>
<tr>
<td>II. Submission Information</td>
<td>7</td>
</tr>
<tr>
<td>A. Where to Obtain the Application Package</td>
<td>7</td>
</tr>
<tr>
<td>B. Pre-Application Submission and Content Form</td>
<td>8</td>
</tr>
<tr>
<td>C. Application Submission Content and Forms</td>
<td>10</td>
</tr>
<tr>
<td>D. Verification of Grants.gov Application in eBRAP</td>
<td>21</td>
</tr>
<tr>
<td>E. Submission Dates and Times</td>
<td>21</td>
</tr>
<tr>
<td>F. Other Submission Requirements</td>
<td>21</td>
</tr>
<tr>
<td>III. Application Review Information</td>
<td>22</td>
</tr>
<tr>
<td>A. Application Review and Selection Process</td>
<td>22</td>
</tr>
<tr>
<td>B. Application Review Process</td>
<td>22</td>
</tr>
<tr>
<td>C. Recipient Qualification</td>
<td>26</td>
</tr>
<tr>
<td>D. Application Review Dates</td>
<td>26</td>
</tr>
<tr>
<td>E. Notification of Application Review Results</td>
<td>26</td>
</tr>
<tr>
<td>IV. Administrative Actions</td>
<td>26</td>
</tr>
<tr>
<td>A. Rejection</td>
<td>26</td>
</tr>
<tr>
<td>B. Modification</td>
<td>26</td>
</tr>
<tr>
<td>C. Withdrawal</td>
<td>27</td>
</tr>
<tr>
<td>D. Withhold</td>
<td>27</td>
</tr>
<tr>
<td>V. Award Administration Information</td>
<td>28</td>
</tr>
<tr>
<td>A. Award Notice</td>
<td>28</td>
</tr>
<tr>
<td>B. Administrative Requirements</td>
<td>28</td>
</tr>
<tr>
<td>C. National Policy Requirements</td>
<td>28</td>
</tr>
<tr>
<td>D. Reporting</td>
<td>28</td>
</tr>
<tr>
<td>E. Award Transfers</td>
<td>28</td>
</tr>
<tr>
<td>VI. Agency Contacts</td>
<td>28</td>
</tr>
<tr>
<td>A. CDMRP Help Desk</td>
<td>28</td>
</tr>
<tr>
<td>B. Grants.gov Contact Center</td>
<td>29</td>
</tr>
<tr>
<td>VII. Application Submission Checklist</td>
<td>30</td>
</tr>
</tbody>
</table>
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

Applications to the Fiscal Year 2014 (FY14) Autism Research Program (ARP) are being solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisitions Activity (USAMRAA). The ARP was established in 2007 to provide support for innovative, high-impact research focused on autism spectrum disorder (ASD). Appropriations for the ARP from FY07 through FY13 totaled $47.42 million (M). The FY14 appropriation is $6M.

The ARP’s vision is to improve the lives of individuals with ASD now by promoting innovative research that advances the understanding of ASD and leads to improved outcomes.

B. FY14 ARP Areas of Interest

The FY14 ARP Areas of Interest are specific for the Clinical Trial Award mechanism only. The FY14 ARP strongly encourages applications that address the critical needs of the ASD community in the following areas:

- Behavioral and other non-pharmacological therapies
- Pharmacological treatments in autism or well-defined subgroups of autism (e.g., genetic, phenotypic, co-occurring conditions)
- Dissemination/Implementation of established, efficacious behavioral interventions
- Therapies to alleviate conditions co-occurring with ASD (e.g., sleep disturbances, gastro-intestinal issues, aggression, depression, anxiety)

C. Award Information

The ARP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other award mechanisms/funding opportunities being offered. The term “human subjects” is used in this Program Announcement/Funding Opportunity to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program

If the clinical trial involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, evidence that an Investigational New Drug (IND) exemption application that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) has been submitted or will be submitted to the
FDA within 90 days of award is required. If the investigational product is a device, evidence that an Investigational Device Exemption (IDE) application that meets all requirements under 21 CFR 812 has been submitted or will be submitted to the FDA within 90 days of award, or that the device is exempt from an IDE, is required. The Government reserves the right to withdraw funding if the IND or IDE application has not been submitted to the FDA within 90 days of the Department of Defense (DoD) award date or if the documented status of the IND or IDE has not been obtained within 9 months of the award date.

The following are important aspects of submission for the Clinical Trial Award:

- The proposed clinical trial is expected to begin no later than 18 months after the award date.
- The proposed intervention to be tested should offer the potential for significant impact for individuals with ASD.
- Inclusion of preliminary data relevant to the proposed research project is required.
- The proposed research project must be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.
- The application should demonstrate availability of, and access to, a suitable patient population that will support a meaningful outcome for the study. The PI should discuss how accrual goals will be achieved and how standards of care may impact the study population.
- The proposed clinical trial design should include clearly defined and appropriate endpoints, and follow Good Clinical Practice (GCP) guidelines.
- The application should demonstrate documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate. The quality of the product should be commensurate with FDA manufacturing standards applicable to the type and phase of product being developed (i.e., Quality System Regulation, Good Manufacturing Practices).
- The application should include a clearly articulated statistical analysis plan, appropriate statistical expertise, and a power analysis reflecting sample size projections, including subpopulation sample sizes, that will clearly answer the objectives of the study.
- The application should include a clearly articulated data management plan, and use of an appropriate database to safeguard and maintain the integrity of the data.
- The application should include a clearly articulated safety management plan, outlining how safety pharmacovigilance will be conducted, if applicable.
- The application should include a study coordinator(s) who will guide the clinical protocol through the local Institutional Review Board (IRB) of record and other regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual.
- The application should include a Transition Plan (including potential funding and resources) showing how the product will progress to the next clinical trial phase and/or delivery to the market after the successful completion of the ARP Clinical Trial Award.
The application should clearly demonstrate strong institutional support.

The application should acknowledge the commitment to filing the study in the National Institutes of Health (NIH) clinical trials registry, [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

**Use of Human Subjects and Human Anatomical Substances:** All DoD-funded research involving new and ongoing research with human subjects and human anatomical substances must be reviewed and approved by the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO), in addition to the local IRB of record. Local IRB approval at the time of submission is NOT required. The HRPO is mandated to comply with specific laws and directives governing all research involving human subjects that is supported by the DoD. These laws and directives will require information in addition to that supplied to the IRB. Allow a minimum of 2-3 months for regulatory review and approval processes. Refer to the General Application Instructions, Appendix 6, for more information.

Investigators are required to submit their data to the National Database for Autism Research (NDAR), which is a secure bioinformatics platform for data sharing for ASD. It is supported by the NIH. For more information, please consult the NDAR at [http://ndar.nih.gov/ndarpublicweb](http://ndar.nih.gov/ndarpublicweb).

*The Congressionally Directed Medical Research Programs (CDMRP) intends that data and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 4, Section L.*

**D. Eligibility Information**

- PIs must be at or above the level of Associate Professor (or equivalent).
- Cost sharing/matching is not an eligibility requirement.
- Eligible investigators must apply through an organization. Organizations eligible to apply include national, international, for-profit, non-profit, public, and private organizations.
- Refer to the General Application Instructions, Appendix 1, for general eligibility information.

**E. Funding**

- The maximum period of performance is 5 years.
- The maximum allowable direct costs for the entire period of performance are $1M plus indirect costs.
- All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.
- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 5 years.
Regardless of the period of performance proposed, the applicant may not exceed the maximum allowable direct costs. Indirect costs shall be proposed in accordance with the organization’s negotiated rate agreement.

Refer to the General Application Instructions, Section II.C.4., for budget regulations and instructions for the Research & Related Budget. For all federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in Section II.C.4. of the General Application Instructions.

For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Salary
- Clinical research costs
- Research supplies
- Equipment
- Travel between collaborating organizations
- Travel costs of up to $1,800 per year to attend scientific/technical meetings

Intramural (DoD), other federal agency, and extramural investigators are encouraged to apply to this Program Announcement/Funding Opportunity. An intramural investigator is defined as a DoD military or civilian employee working within a DoD laboratory or medical treatment facility, or working in a DoD activity embedded within a civilian medical center. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective resource managers. It is permissible for an intramural investigator to be named as a collaborator on an application submitted by an extramural investigator. In such cases, the extramural investigator must include a letter from the intramural collaborator’s Commander or Commanding Officer that authorizes the involvement of the intramural collaborator.

As required of all applicants to this Program Announcement/Funding Opportunity, if PIs from federal agencies submit applications, they must submit through Grants.gov. Therefore, federal applicants must be familiar with Grants.gov requirements, including the need for an active System for Award Management (SAM) registration and a Data Universal Numbering System (DUNS) number. Refer to Appendix 3 of the General Application Instructions for further information regarding Grants.gov requirements.

Awards to extramural organizations will consist solely of assistance agreements (Cooperative Agreements and Grants). Awards to intramural agencies and other federal agencies will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Direct transfer of funds from the recipient to a federal agency is not allowed except under very limited circumstances. Refer to the General Application Instructions, Section II.C.4. Research & Related Budget, for additional information on budget considerations for applications involving federal agencies.
The CDMRP expects to allot approximately $3.2M of the $6M FY14 ARP appropriation to fund approximately two Clinical Trial Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of federal funds for this program.

II. SUBMISSION INFORMATION

Submission is a two-step process requiring both (1) pre-application submission through the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

New for FY14: *The CDMRP has replaced its eReceipt System with eBRAP.* Submission remains a two-step process requiring both pre-application and application submission.

PIs must be registered in eBRAP in order to submit a pre-application and receive notification of the status of a pre-application or application. A key feature of eBRAP is that an organization’s representatives and PIs are able to view and modify the Grants.gov application submissions associated with them, but only if the organization, Business Officials, and PIs are registered and affiliated to the organization in eBRAP (see eBRAP User Guide at https://ebrap.org/eBRAP/public/UserGuide.pdf). Upon completion of an organization’s registration in eBRAP and approval by the CDMRP Help Desk, the organization name will be displayed in eBRAP to assist the organization’s business officials and PIs as they register.

**Note:** Submission of either the pre-application to eBRAP or application to Grants.gov does not require registering an organization and affiliating its Business Officials and PIs in eBRAP; however, the ability to view and modify the Grants.gov application in eBRAP is contingent upon the registration and affiliation. *Application viewing, modification, and verification in eBRAP is strongly recommended, but not required. The Project Narrative and Budget cannot be changed after the application submission deadline. Any other application component cannot be changed after the end of the application verification period.* If verification is not completed by the end of the application verification period, the application will be reviewed as submitted through Grants.gov or may be subject to administrative rejection (see Section IV.A., Rejection).

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application.

A. Where to Obtain the Application Package

To obtain the complete application package, including all required forms, perform a Grants.gov (http://www.grants.gov/) basic search using the Funding Opportunity Number: W81XWH-14-ARP-CTA.
B. Pre-Application Submission and Content Form

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. A change in PI or organization is only permitted for extenuating circumstances and will be decided on a case-by-case basis. If a change in PI or organization is necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

- **Application Information – Tab 1**
- **Application Contacts – Tab 2**
  - It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.
- **Collaborators and Conflicts of Interest (COI) – Tab 3**
  
  FY14 ARP Integration Panel (IP) members should not be involved in any pre-application or application. For questions related to IP members and pre-applications or applications, refer to Section IV.C., Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

- **Required Files – Tab 4**
  
  Notes: Upload document(s) as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.

**Preproposal Narrative (two-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

- **Research Idea:** Concisely state the project’s objective and specific aims. State the FY14 ARP Clinical Trial Award Areas of Interest to be studied or, if the trial does not address an Area of Interest, provide justification that the proposed clinical trial addresses an important problem with respect to individuals with ASD. Briefly describe the proposed project and the population(s) that will be enrolled in the study. Present the reasoning behind the proposed clinical trial, to include relevant
literature citations. Identify the population, access to the population and the recruitment goals. State how this project meets the intent of the program.

- **Intervention:** Describe the intervention to be tested and how it is applicable to the study population.
- **Clinical Impact:** Describe the potential impact of this study on the outcomes of individuals with ASD.
- **Personnel:** State how the background, clinical trial experience, and ASD expertise of the clinical team are appropriate to accomplish the proposed trial (e.g., statistical expertise, expertise in ASD research and clinical studies).

**Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application must be uploaded as individual documents and are limited to:

- **References Cited (one-page limit):** List relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.
- **Key Personnel Biographical Sketches (four-page limit per individual).**

- **Submit Pre-Application – Tab 5**
  This tab must be completed for the pre-application to be accepted and processed.

**Pre-Application Screening**

- **Pre-Application Screening Criteria**
  To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the ARP, pre-applications will be screened based on the following criteria:

  - **Research Idea:** To what extent the rationale and specific aims support the project’s objective. How well the proposed clinical trial addresses one of the FY14 ARP Clinical Trial Award Areas of Interest or provides justification that the proposed clinical trial addresses an important problem with respect to individuals with ASD. To what degree the study population appropriately represents the ASD community and the project’s objective.
  - **Intervention:** To what extent the intervention appears feasible, the potential benefits outweigh potential risks, and outcome measures are appropriate to the intervention and subject population.
  - **Clinical Impact:** To what degree the study will impact the lives of the ASD targeted population. Whether the intervention is applicable to the study population.
○ **Personnel:** How the personnel’s background and expertise are appropriate to accomplish the proposed research (e.g., statistical expertise, expertise in ASD and clinical studies).

- **Notification of Pre-Application Screening Results**
  Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated on the title page of this Program Announcement/Funding Opportunity.

### C. Application Submission Content and Forms

*Applications will not be accepted unless the PI has received notification of invitation.*

Each application submission must include the completed application package of forms and attachments provided in Grants.gov for this Program Announcement/Funding Opportunity. The application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (http://www.grants.gov/).

**New for FY14:** *Applications submitted through and validated by Grants.gov will be retrieved and processed by eBRAP to allow for review, modification, and verification.* The PI and organizational representatives will receive an email request from eBRAP to review, modify, and verify the application submitted to Grants.gov. During this verification period, the PI may upload missing files (excluding those listed in Section IV.A., Rejection), replace files, and re-categorize files. These modifications must be completed by the end of the verification period.

**Note:** *Changes to either the Project Narrative or Budget are not allowed in eBRAP.* If such changes are required, the entire application package must be submitted through Grants.gov as a “Changed/Corrected Application” with the Previous Grants.gov Tracking ID prior to the application submission deadline (which occurs earlier than the end of the application verification period).

**Grants.gov application package components:** For the Clinical Trial Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. **SF 424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

2. **Attachments Form**

   *The Project Narrative is NOT the formal clinical trial protocol. Instead, all essential elements of the proposed clinical trial necessary for scientific review must be included as directed in Attachment 1 (the Project Narrative) and Attachments 6-8 described below. Failure to submit these attachments as part of the application package will result in rejection of the entire application.*
• **Attachment 1: Project Narrative (20-page limit):** Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and will result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below.

○ **Background:** Describe in detail the rationale for the study and include a literature review, preliminary studies, and/or preclinical data that provide the basis for the proposed clinical trial. The background section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses. This section should establish the relevance of the study and explain the applicability of the proposed findings. Describe the planned indication for the product label, if applicable, and include an outline of the development plan required to support that indication.

If the proposed clinical trial was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically identify the portions of the study that will be supported with funds from this award.

○ **Objectives/Specific Aims/Hypotheses:** Provide a description of the purpose and objectives of the study with detailed specific aims and/or study questions/hypotheses.

○ **Study Design:** Describe the type of study to be performed (e.g., prospective, randomized, controlled) and outline the proposed methodology in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate.

  – Identify the intervention to be tested and describe the projected outcomes.
  – Define the study variables and describe how they will be measured. Include a description of appropriate controls and the endpoints to be tested.
  – Describe the methods that will be used to recruit a sample of human subjects from the accessible population (e.g., convenience, simple random, stratified random).
  – Describe the human subject-to-group assignment process (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group, or other procedures), if applicable. Explain the specific actions to accomplish the group assignment (e.g., computer assignment, use of table of random numbers).
  – If using psychometric measures, describe their reliability and validity.

○ **Statistical Plan and Data Analysis:** Describe the statistical model, how it is appropriate to the study, and the data analysis plan with respect to the study objectives. Include a complete power analysis to demonstrate that the sample...
size is appropriate to meet the objectives of the study. Specify the approximate number of human subjects that will be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study (e.g., defined subpopulation from a named group such as “baby-sibs”). Describe the data analysis plan in a manner that is consistent with the study objectives.

• Attachment 2: Supporting Documentation. Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested may result in the removal of those items or administrative withdrawal of the application.
  
  ○ References Cited: List the references cited (including URLs if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
  
  ○ List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.
  
  ○ Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.
  
  ○ Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then a copy/copies of the published manuscript(s) must be included in Attachment 2. Extra items will not be reviewed.
  
  ○ Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project.
  
  ○ Letters of Collaboration: Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.
  
  ○ Intellectual Property
  
  – Background and Proprietary Information: All software and data first produced under the award are subject to a federal purpose license in accordance with applicable DoD Grant and Agreement Regulations (DoDGAR) requirements. Provide a list of all background intellectual property to be used in the project or provide a statement that none will be
used. If applicable, state and identify the proprietary information that will be provided to the Government and indicate whether the applicant will require a waiver of the federal purpose license.

- Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 4, Section L, for more information about the CDMRP expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.”
  Technical abstracts should be written using the outline below. The technical abstract is used by all reviewers; however, programmatic reviewers do not typically have access to the full application and rely on the technical abstract for appropriate description of the project’s key aspects.
  - Background: Present the ideas and reasoning behind the proposed work.
  - Objective/Hypothesis: State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.
  - Specific Aims: State the specific aims of the study.
  - Study Design: Briefly describe the study design including appropriate controls.
  - Clinical Impact: Briefly describe how the proposed project will have an impact on ASD research or patient care.

- **Attachment 4: Lay Abstract (one-page limit):** Upload as “LayAbs.pdf.”
  The lay abstract is used by all reviewers. Of particular importance, programmatic reviewers do not have access to the full application and therefore rely on the lay abstract for appropriate description of the project’s key aspects.
  Lay abstracts should be written using the outline below.
  - Clearly describe, in a manner readily understood by lay persons, the rationale and objective for the proposed work.
    - Do not duplicate the technical abstract.
  - Describe the ultimate applicability and impact of the research.
    - What types of patients will it help, and how will it help them?
    - What are the potential clinical applications, benefits, and risks?
    - Briefly describe how the proposed project will have an impact on ASD research and patient care.
• **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.” Refer to the General Application Instructions, Section II.C.2., for detailed guidance on creating the SOW.

The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Program Announcement and Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). For the Clinical Trial Award mechanism, use the SOW format example titled “SOW for Clinical Research (Including Trials, Special Populations).” The SOW must be in PDF format prior to attaching.

• **Attachment 6: Human Subject Recruitment and Safety Procedures (no page limit):** Upload as “HumSubProc.pdf.” The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.

  a. **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site (population from whom the sample will be recruited/drawn). Demonstrate that the research team has access to the proposed study population. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical trials (if applicable). Address any potential barriers to accrual and plans for addressing unanticipated delays. Include justification of any age, race, ethnicity, or sex limitations provided.

  b. **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical trial. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

    *Inclusion of Women and Minorities in Study.* Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRMC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Include an appropriate justification if women and/or minorities will be excluded from the clinical trial.

  c. **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, health care provider identification).

    • Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.

    • Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study.
• Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.

d. Description of the Informed Consent Process: Specifically describe the plan for obtaining informed consent from human subjects.

• For the proposed study, provide a draft, in English, of the Informed Consent Form.

• Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the trial.

• Include information regarding the timing and location of the consent process.

• Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.

• Address how privacy and time for decision making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.

• Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.

• Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: The PI must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical trial to be in compliance with Title 10 United States Code Section 980 (10 USC 980) (http://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf). If applicable, please refer to the General Application Instructions, Appendix 5, for more information.

• Assent. If minors or other populations that cannot provide informed consent are included in the proposed clinical trial, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

e. Screening Procedures: List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry.
Please note that some screening procedures may require a separate consent or a two-stage consent process. Informed consent must be obtained prior to initiation of any procedures for the purpose of determining eligibility.

f. Risks/Benefits Assessment:

- **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is subjected to as a result of participation in the clinical trial. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.

- **Risk management and emergency response:**
  - Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
  - Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
  - Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, to include who will be responsible for the cost of such care.
  - Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).
  - Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.

- **Potential benefits:** Describe known and potential benefits of the study to the human subject, a specific community, or society.

- **Attachment 7: Intervention (no page limit):** Upload as “Intervention.pdf.” The Intervention attachment should include the components listed below.

  a. **Description of the Intervention:** As applicable, the description of the intervention should include the following components: complete name and composition, storage and handling information, source, dose, schedule, administration route, washout period, duration of the intervention, and concomitant medications allowed. Describe any biobehavioral interventions including the modality of the intervention, duration of the intervention, and measurement of the outcomes such as the identification of assessment instruments. Description of devices should include detailed operational instructions, any potential risks to users, and intended benefits. Other types of interventions should be fully described.
Summarize key preclinical pharmacological findings, dosage studies, and other clinical studies (if applicable) that examine the safety of the intervention.

b. **Study Procedures:** Describe the interaction with the human subject to include the study intervention that he/she will experience. Provide sufficient detail in chronological order for a person uninvolved in the study to understand what the human subject will experience. Provide a schedule (e.g., flowchart or diagram) of study evaluations and follow-up procedures. Discuss how compliance with Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP), and other regulatory considerations will be established, monitored, and maintained, as applicable.

c. **Clinical Monitoring Plan:** Describe how the study will be conducted by and monitored for ICH E6 (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) Good Clinical Practices (GCP) compliance, by an independent clinical trial monitor (or clinical research associate). The monitoring plan should describe the types of monitoring visits to be conducted, the intervals (based on level of risk), how corrective actions will be reported to the Sponsor and PI, and how they will be corrected and prevented by the clinical trial site/PI.

- **Attachment 8: Data Management (no page limit):** Upload as “Data_Manage.pdf.” The Data Management attachment should include the components listed below.

  a. **Data Management:** Describe all methods used for data collection to include the following:

     - **Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.

     - **Confidentiality:**
       - Explain measures taken to protect the privacy of study human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
       - Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of USAMRMC are eligible to review study records.
       - Address requirements for reporting sensitive information to state or local authorities.

     - **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the
integrity of the data. For FDA-regulated studies, compliance with 21 CFR 11 is required.

- **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, to include results from any screening or diagnostic tests performed as part of the study.

b. **Laboratory Evaluations:**

- **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.

- **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).

- **Storage:** Describe specimen storage, to include location of storage, how long specimens will be stored, any special conditions required, labeling, and disposition. Outline the plan to store specimens for future use to include considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

- **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

- **Attachment 9: Study Personnel and Organization (no page limit):** Start each document on a new page. Combine into one document and upload as “Personnel.pdf.” The Study Personnel and Organization attachment should include the components listed below.

  a. **Organizational Chart:** Provide an organizational chart identifying key members of the study team including institution/center/department and name each person’s position on the project. A medical monitor (external to the study and not reimbursed by the study) and study coordinator(s) should be included. If applicable, include any external consultants or other experts who will assist with FDA applications. While there is no specified format for this information, a table(s) or diagram is recommended. Note: This item may be made available for programmatic review.

  b. **Study Personnel Description:** Briefly describe the roles of the individuals listed in the organizational chart on the project. Describe relevant experience and qualifications that demonstrate appropriate expertise for the given role.
c. Study Management Plan: Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). If the proposed clinical trial is multi-institutional, plans for communication and data transfer between the collaborating institutions, as well as how data, specimens, and/or imaging products obtained during the study will be handled, should be included. Provide a plan for real-time communication among collaborating institutions (if applicable).

- Attachment 10: Surveys, Questionnaires, and Other Data Collection Instruments, if applicable (no page limit): Upload as “Surveys.pdf.” The Surveys, Questionnaires, and Other Data Collection Instruments attachment should include a copy of the most recent version of surveys, questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information collected is related to the objectives of the study.

  - Identify the volunteer population(s) that will participate in the proposed intervention, and describe the potential impact of the proposed clinical trial on the outcomes of individuals with ASD.
  - Describe the short-term impact: Detail the anticipated outcomes that will be directly attributed to the results of the proposed clinical trial.
  - Describe the long-term impact: Explain the long-range vision for implementation of the intervention in the clinic or field, and describe the anticipated long-term benefits for the targeted population.
  - Compare the proposed intervention to pharmacologic agents, devices, and/or clinical guidance currently available, if applicable.

- Attachment 12: Transition Plan (one-page limit): Upload as “Transition.pdf.” Provide information on the methods and strategies proposed to move the product or knowledge outcomes to the next phase of clinical trials, commercialization, and/or delivery to the civilian or military market after successful completion of the award. The transition plan should include the components listed below.
  - Details of the funding strategy that will be used to bring the outcomes to the next level of clinical trials and/or delivery to market (e.g., specific potential industry partners, specific funding opportunities to be applied for). Provide an outline for the development of the intervention for the indication beyond the limits of the trial.
  - A description of collaborations and other resources that will be used to provide continuity of development.
  - A brief schedule and milestones for bringing the outcome(s) to the next phase of clinical trials and/or delivery to the military or civilian market, including when it can be anticipated to be transitioned to an industry partner or approved by the FDA, if applicable.

- State whether the trial requires regulation by the FDA. If FDA regulation is required, describe the planned indication for the proposed product and whether an IND/IDE is necessary. If an IND or IDE is required, state the plan for submittal and timeline.
- If an IND or IDE application has been submitted, provide an explanation of the status of the IND or IDE application (e.g., past the critical 30-day period, pending response to questions raised by the Agency, on clinical hold). Provide a summary of previous meetings with the FDA on development of this product, if appropriate. A copy of the Agency meeting minutes should be included if available. Provide copies of communications from the FDA relevant to the most recent status of the IND or IDE application.
- If the IND or IDE application is not yet submitted, provide evidence that an IND or IDE will be submitted within 90 days of award. Examples include results and minutes of a pre-IND or pre-IDE meeting with the FDA, a pre-IND/pre-IDE meeting request to the FDA, or other communication with the FDA. Provide the anticipated date of IND/IDE submission.
- If an IND or IDE is not required for the proposed study, provide evidence in the form of communication from the FDA or the IRB of record to that effect.

Attachment 14: NDAR Submission Plan (two-page limit): Upload as “NDAR.pdf”

- Provide a plan for submission of human subject data to NDAR, including information on security of personal information (Health Insurance Portability and Accountability Act [HIPAA]) and data sharing for the bioinformatics platform. Please consult NDAR at http://ndar.nih.gov/ndarpublicweb.

3. Research & Related Senior/Key Person Profile (Expanded): Refer to the General Application Instructions, Section II.C.3., for detailed information.

- PI Biographical Sketch (four-page limit): Upload as “Biosketch_LastName.pdf.”
- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”
- Key Personnel Biographical Sketches (four-page limit each): Upload as “Biosketch_LastName.pdf.”
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

4. Research & Related Budget: Refer to the General Application Instructions, Section II.C.4., for detailed information.

- Budget Justification (no page limit): Upload as “BudgetJustification.pdf.”
5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C.5., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C.6., for detailed information.

**D. Verification of Grants.gov Application in eBRAP**

For FY14, a new process has been initiated whereby organizational representatives and PIs can view their applications as submitted through Grants.gov and prior to peer review of the application. This will enable applicants to make modifications prior to scientific and programmatic evaluation of applications, provided the modifications are made by either the end of the application verification period or, for changes to the Project Narrative or Budget, by the application submission deadline.

After application submission to Grants.gov, eBRAP will retrieve and validate the application submission. eBRAP will notify the organizational representatives and PI via email and instruct them to log into eBRAP to review, modify, and verify the application. Files that fail eBRAP validation will be noted in both the email and in the Full Application Files tab. eBRAP does not validate the accuracy or completeness of content in the files. PIs are strongly encouraged to review all application components. If either the Project Narrative or the Budget fail eBRAP validation, an updated Grants.gov application package must be submitted via Grants.gov prior to the application submission deadline, which occurs earlier than the end of the application verification period. *The Project Narrative and Budget cannot be changed after the application submission deadline. Any other application component cannot be changed after the end of the application verification period.*

**E. Submission Dates and Times**

All submission dates and times are indicated on the **title page** of this Program Announcement/Funding Opportunity. Pre-application and application submissions are required. Failure to meet either of these deadlines will result in application rejection.

**F. Other Submission Requirements**

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Appendix 3, for information on Grants.gov requirements.
III. APPLICATION REVIEW INFORMATION

A. Application Review and Selection Process

All applicants are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, U.S. Army Medical Research and Materiel Command (USAMRMC), based on (a) technical merit and (b) the relevance to the mission of the DHP and ARP and to the specific intent of the award mechanism. The highestscoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a non-disclosure statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

B. Application Review Process

1. Peer Review: To determine technical merit, all applications will be evaluated according to the following scored criteria, of which Scientific Merit is the most important criterion, followed by all other listed criteria, which are of equal importance.

   *Note that impact does not compensate for deficiencies in scientific merit.* A statistician will be included on all scientific review panels.

   - **Scientific Merit**
     - How well the scientific rationale for testing the intervention is supported by the preliminary data, critical review and analysis of the literature, and/or laboratory and/or preclinical evidence.
     - How well the study aims, hypotheses or objectives, experimental design, methods, data collection procedures, and analyses are designed to clearly answer the clinical objective, including selection of an appropriate control condition(s) for comparison.
     - How well the inclusion and randomization criteria meet the needs of the proposed clinical trial.
     - How well the exclusion criteria are justified.
• **Statistical Plan**
  ○ To what degree the statistical plan, including sample size projections and power analysis, is adequate for the study and all proposed correlative studies.
  ○ Whether the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.

• **Clinical Impact**
  ○ How well the sample population represents the targeted patient population that might benefit from the proposed intervention.
  ○ To what degree the potential outcomes of the proposed clinical trial will provide/improve the short-term benefits for individuals.
  ○ To what degree the long-term benefits of the intervention may impact patient care and/or quality of life.
  ○ How well the proposed clinical trial addresses one or more of the FY14 Clinical Trial Award Areas of Interest or provides justification that the proposed clinical trial addresses an important problem for individuals with ASD.

• **Ethical Considerations**
  ○ How well the level of risk to human subjects is minimized and whether there is sufficient evidence of a monitoring plan that is appropriate for the level of risk.
  ○ How well the evidence shows that the procedures are consistent with sound research design and, when appropriate, that these procedures are already in use for diagnostic or treatment purposes.
  ○ To what degree privacy issues are appropriately considered.
  ○ To what degree the process for seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.

• **Intervention**
  ○ To what degree the intervention addresses the clinical need(s) described.
  ○ How well the intervention advances patient care beyond the currently available interventions and/or standards of care.
  ○ To what degree the intensity, dose, frequency, duration, etc., of the intervention can be quantified to achieve replicable, clinically significant outcomes over a meaningful, well-defined follow-up or observation period.
  ○ To what degree the PI has provided preclinical and/or clinical evidence to support the safety of the intervention.
  ○ Whether a member of the study team holds the IND/IDE and whether the timeline proposed for IND/IDE application is appropriate (if applicable).
○ For investigator-sponsored INDs, whether there is institutional support to serve as a sponsor and whether they are equipped to assume the monitoring required by the FDA (if applicable).

○ Whether measures are described to ensure the consistency of dosing of active ingredients for nutritional supplements (if applicable).

○ To what degree the data collection instruments (e.g., surveys, questionnaires, etc.), if applicable, are appropriate to the proposed study.

○ To what extent the data and safety monitoring plan will sufficiently review and manage the collected data, and maintain safety protocols.

○ If applicable, whether plans to comply with GMP, GLP, and GCP guidelines are appropriate.

• **Recruitment, Accrual, and Feasibility**
  ○ Whether the PI has demonstrated access to the proposed human subjects population.
  ○ How well the PI addresses the availability of human subjects for the clinical trial and the prospect of their participation.
  ○ To what degree the recruitment, informed consent, screening, and retention processes for human subjects will meet the needs of the proposed clinical trial.
  ○ To what extent possible delays and evidence of an adequate mitigation plan to resolve potential delays (e.g., slow accrual, attrition) are identified.
  ○ To what extent the proposed clinical trial affects the daily lives of the individual human subjects participating in the study (e.g., Will human subjects still be able to take their regular medications while participating in the clinical trial? Are human subjects required to stay overnight in a hospital?).

• **Personnel and Communication**
  ○ Whether the composition of the study team (e.g., study coordinator, statistician) is appropriate.
  ○ To what degree the study team’s background and expertise are appropriate to accomplish the proposed work (e.g., statistical expertise, expertise in the disease, and clinical studies).
  ○ How the levels of effort of the study team members are appropriate for successful conduct of the proposed trial.
  ○ To what degree the logistical aspects of the proposed clinical trial (e.g., communication plan, data transfer, standardization of procedures) meet the needs of the proposed clinical trial.

• **Transition Plan**
  ○ Whether the funding strategy described to bring the outcome(s) to the next level of clinical trials and/or delivery to market is appropriate.
o Whether appropriate collaborations and other resources for providing continuity of development are established and/or well described.

o How the schedule and milestones for bringing the outcome(s) to clinical trial and/or delivery to market is appropriate.

o How well the potential risk analysis for cost, schedule, manufacturability, and sustainability is developed.

o How well the application identifies intellectual property ownership, describes any appropriate intellectual and material property plan among participating organizations (if applicable), and addresses any impact of intellectual property issues on product development and subsequent Government access to products supported by this Program Announcement/Funding Opportunity.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

• Environment
  o To what degree the scientific environment, clinical setting, and the accessibility of institutional resources support the clinical trial at each participating center or institution (including collaborative arrangements).
  o Whether there is evidence for appropriate institutional commitment from each participating institution.
  o If applicable, to what degree the intellectual and material property plan that is agreed upon by each participating institution is appropriate for the proposed clinical trial.

• Budget
  o Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.

• Application Presentation
  o To what extent the writing, clarity, and presentation of the application components influence the review.

2. Programmatic Review: To make funding recommendations, the following equally considered criteria are used by programmatic reviewers:

a. Ratings and evaluations of the peer reviewers

b. Relevance to the mission of the DHP and FY14 ARP, as evidenced by the following:
  • Adherence to the intent of the award mechanism
  • Programmatic relevance
  • Program portfolio composition
  • Relative impact
C.  **Recipient Qualification**

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

D.  **Application Review Dates**

All application review dates and times are indicated on the [title page](#) of this Program Announcement/Funding Opportunity.

E.  **Notification of Application Review Results**

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

IV.  **ADMINISTRATIVE ACTIONS**

After receipt of pre-applications from eBRAP or applications from Grants.gov, the following administrative actions may occur:

A.  **Rejection**

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- Human Subject Recruitment and Safety Procedures (Attachment 6) is missing.
- Intervention (Attachment 7) is missing.
- Data Management (Attachment 8) is missing.

B.  **Modification**

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.
Following application submission to Grants.gov, the PI will receive an email request from eBRAP to review, modify, and verify the application submitted to Grants.gov. During this verification period, the PI may upload missing documents (excluding those listed in Section IV.A., Rejection), replace files, and re-categorize files. These modifications must be completed by the end of the application verification period; otherwise, the application will be reviewed as submitted.

C. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- A FY14 ARP Integration Panel (IP) member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY14 ARP IP members can be found at http://cdmrp.army.mil/arp/panels/panels14.
- The application fails to conform to this Program Announcement/Funding Opportunity description to the extent that appropriate review cannot be conducted.
- Direct costs as shown on the Research & Related Budget exceed the maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- Inclusion of any employee of CDMRP review contractors in applications for funding without adequate plans to mitigate conflicts of interest. Refer to the General Application Instructions, Section II.B., for detailed information.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
- The proposed research is not a clinical trial.
- The PI does not meet the eligibility criteria.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than September 30, 2015. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

B. Administrative Requirements

Refer to the General Application Instructions, Appendix 4 for general information regarding administrative requirements.

C. National Policy Requirements

Refer to the General Application Instructions, Appendix 5 for general information regarding national policy requirements.

D. Reporting

Refer to the General Application Instructions, Appendix 4, Section J, for general information on reporting requirements.

Quarterly technical progress reports will be required.

E. Award Transfers

The institution transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

VI. AGENCY CONTACTS

A. CDMRP Help Desk

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507
Email: help@eBRAP.org
B. Grants.gov Contact Center

Questions related to application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726
Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the application package. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
### VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF-424 (R&amp;R) Application for Federal Assistance</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Attachments Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF-424 (R&amp;R) Attachments Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name &quot;ProjectNarrative.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name &quot;Support.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name &quot;TechAbs.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name &quot;LayAbs.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name &quot;SOW.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Subject Recruitment and Safety Procedures: Upload as Attachment 6 with file name &quot;HumSubProc.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention: Upload as Attachment 7 with file name &quot;Intervention.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Management: Upload as Attachment 8 with file name &quot;Data_Manage.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Personnel and Organization: Upload as Attachment 9 with file name &quot;Personnel.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveys, Questionnaires, and Other Data Collection Instructions: Upload as Attachment 10 with file name &quot;Surveys.pdf,&quot; if applicable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact Statement: Upload as Attachment 11 with file name &quot;Impact.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Plan: Upload as Attachment 12 with file name &quot;Transition.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND/IDE Documentation: Upload as Attachment 13 with file name &quot;IND-IDE.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDAR Submission Plan: Upload as Attachment 14 with file name &quot;NDAR.pdf.&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R &amp; R Subaward Budget Attachment(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>